X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 26.1 34.0 76.8% View Chart
P/BV x 3.6 3.1 117.8% View Chart
Dividend Yield % 0.7 0.6 132.0%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
CIPLA
Mar-18
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,788663 420.5%   
Low Rs1,902479 397.0%   
Sales per share (Unadj.) Rs860.8189.0 455.4%  
Earnings per share (Unadj.) Rs57.117.6 324.3%  
Cash flow per share (Unadj.) Rs122.034.0 358.5%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %0.90.5 162.3%  
Book value per share (Unadj.) Rs757.7176.7 428.7%  
Shares outstanding (eoy) m165.91805.12 20.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.73.0 90.2%   
Avg P/E ratio x41.132.5 126.6%  
P/CF ratio (eoy) x19.216.8 114.5%  
Price / Book Value ratio x3.13.2 95.8%  
Dividend payout %35.017.1 205.5%   
Avg Mkt Cap Rs m389,034459,724 84.6%   
No. of employees `00023.523.6 99.6%   
Total wages/salary Rs m32,14926,901 119.5%   
Avg. sales/employee Rs Th6,070.86,446.1 94.2%   
Avg. wages/employee Rs Th1,366.61,139.4 119.9%   
Avg. net profit/employee Rs Th402.5600.0 67.1%   
INCOME DATA
Net Sales Rs m142,810152,193 93.8%  
Other income Rs m1,5523,577 43.4%   
Total revenues Rs m144,362155,769 92.7%   
Gross profit Rs m23,51228,264 83.2%  
Depreciation Rs m10,77213,228 81.4%   
Interest Rs m7881,142 69.0%   
Profit before tax Rs m13,50417,470 77.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m344-28 -1,237.4%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m4,3802,501 175.1%   
Profit after tax Rs m9,46814,166 66.8%  
Gross profit margin %16.518.6 88.7%  
Effective tax rate %32.414.3 226.6%   
Net profit margin %6.69.3 71.2%  
BALANCE SHEET DATA
Current assets Rs m104,984108,141 97.1%   
Current liabilities Rs m68,93838,322 179.9%   
Net working cap to sales %25.245.9 55.0%  
Current ratio x1.52.8 54.0%  
Inventory Days Days7497 76.6%  
Debtors Days Days10474 139.2%  
Net fixed assets Rs m104,385109,411 95.4%   
Share capital Rs m8301,610 51.5%   
"Free" reserves Rs m124,886140,682 88.8%   
Net worth Rs m125,716142,292 88.4%   
Long term debt Rs m25,08936,621 68.5%   
Total assets Rs m225,443228,606 98.6%  
Interest coverage x18.116.3 111.3%   
Debt to equity ratio x0.20.3 77.5%  
Sales to assets ratio x0.60.7 95.2%   
Return on assets %4.56.7 67.9%  
Return on equity %7.510.0 75.7%  
Return on capital %9.710.0 97.5%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62351,691 140.5%   
Fx outflow Rs m18,91621,033 89.9%   
Net fx Rs m53,70730,658 175.2%   
CASH FLOW
From Operations Rs m18,03014,628 123.3%  
From Investments Rs m-14,883-8,540 174.3%  
From Financial Activity Rs m-4,440-3,855 115.2%  
Net Cashflow Rs m-1,2362,431 -50.8%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 17, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS